Antithrombin III (ATIII) replacement therapy in patients with sepsis and/or postsurgical complications: a controlled double-blind, randomized, multicenter study.
about
Antithrombin III for critically ill patientsAntithrombin III for critically ill patientsThe limitations of observational studies on the treatment of severe sepsisAntithrombin III in patients admitted to intensive care units: a multicenter observational study.Bench-to-bedside review: endothelial cell dysfunction in severe sepsis: a role in organ dysfunction?Recent acquisitions in the pathophysiology, diagnosis and treatment of disseminated intravascular coagulation.Sepsis and disseminated intravascular coagulationApheresis of plasma compounds as a therapeutic principle in severe sepsis and multiorgan dysfunction syndrome.A randomized, controlled, multicenter trial of the effects of antithrombin on disseminated intravascular coagulation in patients with sepsisManagement of the critically ill patient with severe sepsis.The host response to sepsis and developmental impactAcquired antithrombin deficiency in sepsis.Postoperative activity, but not preoperative activity, of antithrombin is associated with major adverse cardiac events after coronary artery bypass graft surgeryAntithrombin III for critically ill patients: a systematic review with meta-analysis and trial sequential analysis.Clinical trials of immunomodulatory therapies in severe sepsis and septic shock.Utility of thromboelastography and/or thromboelastometry in adults with sepsis: a systematic review.Four-day antithrombin therapy does not seem to attenuate hypercoagulability in patients suffering from sepsis.Current understanding of disseminated intravascular coagulation.Comparison of mechanisms after post-hoc analyses of the drotrecogin alfa (activated) and antithrombin III trials in severe sepsis.Update on the treatment of disseminated intravascular coagulation.Analysis of the influence of antithrombin on microvascular thrombosis: anti-inflammation is crucial for anticoagulationClinical review: molecular mechanisms underlying the role of antithrombin in sepsis.Pharmacotherapy of acute lung injury and the acute respiratory distress syndrome.Studies on therapeutic effects and pathological features of an antithrombin preparation in septic disseminated intravascular coagulation patients.Emerging role of anticoagulants and fibrinolytics in the treatment of acute respiratory distress syndromeEffects of anticoagulant strategies on activation of inflammation and coagulation.Intracellular and extracellular serpins modulate lung disease.Dysregulation of coagulation in cerebral malaria.Septic shock: new pharmacotherapy options or better trial design?The role of serpin and cystatin antiproteases in mucosal innate immunity and their defense against HIV.Efficacy and safety of anticoagulant therapy in three specific populations with sepsis: a meta-analysis of randomized controlled trials.Antimicrobial effects of helix D-derived peptides of human antithrombin IIIRecommendations for the use of antithrombin concentrates and prothrombin complex concentratesWhen acquired thrombophilia mattered.Enoxaparin versus unfractioned heparin as anticoagulant for continuous venovenous hemodialysis: a randomized open-label trial.Use of recombinant human soluble thrombomodulin in patients with sepsis-induced disseminated intravascular coagulation after intestinal perforation.Antithrombosis Trials: Should we test therapeutic heparin adjusted based on activated partial thromboplastin time in septic shock?Antithrombin and heparin may limit the activation of Protein C.Coagulation deficiencies: a look to the future.Antithrombotic agents in the treatment of severe sepsis.
P2860
Q24186159-08C02ED0-75AE-46B9-BD79-01DEB1B37183Q24242053-410BA190-5298-4A6A-8240-23D26A269E29Q24791014-54829D42-0D87-470F-BF35-5840744B4A9DQ24792729-ED496770-796B-47FE-AD75-7011728071C4Q24794238-C34311D6-6540-452C-AD6E-37F3D05C9241Q25255548-7A0EE3A3-B22B-43FE-A84C-D259F71C62B7Q26751555-BF1B5EBA-3F26-4FEA-9C82-8B6F99D654D9Q33649871-853FD60D-799A-459D-88E5-FA617CE86202Q33753012-94CD0387-1A38-42A2-AF0C-83C54335ACD2Q33840109-AB4A1903-37A5-4668-A0C6-C30329E1CEA1Q33950741-6A6C076A-52AC-4CAA-A96E-232A341689AEQ34135317-54711FBE-DC6B-4DA7-AEB6-338C63B64775Q34441153-63AF710B-6B6A-476F-81C6-AF7D727F84ADQ34513234-78AE7A48-D593-485C-87B9-5DE154291898Q34577529-8B7CB73F-57AF-45E7-9CF7-4B730BFACA3BQ35089987-FAE7A513-B28B-40A9-8CC5-9356EBA6131EQ35629861-CB2E9801-6255-41C5-A214-FA96E5550DBFQ35661014-8B64E6E9-8980-4A6E-B0D0-F8902006459DQ35794980-FFDC48C4-667A-45CE-A781-E96F70159E75Q35809195-55AF7387-8458-441A-A961-CEE5C6DFD3E6Q35829030-D6B55170-B5FE-4490-A3C8-59C0FFB1B7B4Q36423261-13C6500F-6D9C-4A3D-BA31-8755F8401870Q36467694-9C87FF84-D522-4A59-B3EF-48B597248608Q36793063-3852E4DA-46C0-4D9A-B5F9-F3A72EFC072AQ36835719-81251582-2ED7-4A29-8979-428E859E71DAQ36842724-4623310E-7895-405C-9A0D-EDF8D0C82ADDQ37341652-70D9C2AD-72A0-43AD-8A43-403A50C210F2Q37487007-CAC89E55-A30B-4930-B13D-EEBBC8657A5AQ38085693-6B99F6E2-C273-4F67-AF35-7C0EFB44F873Q38170193-5F3C5707-E89D-47DE-A1DA-A7CC88F7F350Q38670135-278048AD-AADD-4D95-BAF8-F9C2CBFE9D04Q41747279-032DD7B6-6DEB-46B4-95CE-194172C1088AQ42096335-070D5456-4E57-4865-AC79-C4FA6D74C67EQ43003934-32CF0932-4694-480E-BA0F-331FA91378A5Q43108541-78F1F302-BA49-42D4-B4D0-D17626168EA0Q43163829-CF08BFA6-4C01-473A-9D46-81DD14992362Q43206206-835B8DAF-0A51-46D9-8CD2-60E4E7F63FD3Q43457307-1EC63EDC-73D2-49F7-A70E-7B92B2FA218FQ43517013-DA323ADA-8494-466C-937E-FCB227999E38Q46576624-A1082A22-6E89-45F5-BA08-105B21EDD044
P2860
Antithrombin III (ATIII) replacement therapy in patients with sepsis and/or postsurgical complications: a controlled double-blind, randomized, multicenter study.
description
1998 nî lūn-bûn
@nan
1998年の論文
@ja
1998年学术文章
@wuu
1998年学术文章
@zh
1998年学术文章
@zh-cn
1998年学术文章
@zh-hans
1998年学术文章
@zh-my
1998年学术文章
@zh-sg
1998年學術文章
@yue
1998年學術文章
@zh-hant
name
Antithrombin III (ATIII) repla ...... randomized, multicenter study.
@en
Antithrombin III (ATIII) repla ...... randomized, multicenter study.
@nl
type
label
Antithrombin III (ATIII) repla ...... randomized, multicenter study.
@en
Antithrombin III (ATIII) repla ...... randomized, multicenter study.
@nl
prefLabel
Antithrombin III (ATIII) repla ...... randomized, multicenter study.
@en
Antithrombin III (ATIII) repla ...... randomized, multicenter study.
@nl
P2093
P2860
P356
P1476
Antithrombin III (ATIII) repla ...... randomized, multicenter study
@en
P2093
F de Cataldo
G Gallioli
G Palareti
P2860
P2888
P304
P356
10.1007/S001340050576
P577
1998-04-01T00:00:00Z